Epigenomics reports Tamoxifen treatment response test study results inconclusive
Initial analysis of the data strongly points towards issues with the technical protocols followed rather than problems with the markers themselves. In addition, the collected data shows irregularities with sample quality and input DNA concentrations which led to an unusually high rate of sample exclusions. The markers were observed when samples with low concentrations of input DNA were excluded. A body of strong clinical data strengthens this notion as the PITX2 marker used in the test has previously been identified and validated in a number of independent studies totalling approximately 1200 patients.
Epigenomics and partner Roche Diagnostics are jointly conducting data analysis and additional experimenents. Epigenomics expects to need no more than a few months to investigate the technical issues and then successfully run a further study within another 6 to 9 months to resolve the situation. Roche Diagnostics has an option to license the Tamoxifen treatment response test as part of its multi diagnostic product development collaboration with Epigenomics.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.